Investigational drug · Phase 2
TS23
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Ischemic Stroke, Pulmonary Embolism.
Phase 2Last checked: Nov 19, 2026Latest source record: Oct 19, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
4
Any phase or sponsor naming "TS23"
First trial start
2023
May 24, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "TS23", any sponsor or status.
Conditions studied
As listed on its trial records.
- Ischemic Stroke
- Pulmonary Embolism
Approved drugs for the same conditions: Blood clots (DVT and pulmonary embolism) · Stroke prevention · Cardiovascular and metabolic
Largest trials
Live from ClinicalTrials.gov: studies naming "TS23" as an intervention, largest first.
- Strategy for Improving Stroke Treatment ResponsePivotal-lookingRecruiting
Translational Sciences, Inc.Industry
NCT05948566 · 300 participants (planned) · Start Mar 18, 2024 · Primary completion Jul 2028
Drug: TS23 · For: Ischemic Stroke
Sites: Birmingham, Alabama; Phoenix, Arizona; Tucson, Arizona · 52 sites in all
- Novel α2-Antiplasmin Inactivation for Lysis of Intravascular Thrombi (NAIL-IT) TrialActive, not recruiting
Translational Sciences, Inc.Industry
NCT05408546 · 64 participants (planned) · Start May 24, 2023 · Primary completion Aug 31, 2026
Drug: TS23; Placebo · For: Pulmonary Embolism
Sites: Phoenix, Arizona; Tucson, Arizona; Los Angeles, California · 13 sites in all
Translational Sciences, Inc.Industry
NCT03001544 · 24 participants · Start Jul 2015 · Primary completion Jun 2016
Drug: TS23 · For: Thrombosis; Cerebral Ischemia; Venous Thrombosis and 2 more
Daiichi SankyoDaiichi Sankyo (DSNKY)
NCT03316729 · 0 participants · Start Jan 2018 · Primary completion Feb 2020
Drug: DS-9231; Placebo · For: Pulmonary Embolism
Newest research
PubMed records naming it or its code names, newest first.
- Small Town, Big Lessons-A Blended Supervision Placement Reflection.
Stocker J · Emerg Med Australas 2026
- An emerging family of immunogenic epitopes in Chagas disease.
Markosian C, Giordano RJ, Pasqualini R, et al. · Trends Parasitol 2026
- A Trypanosoma cruzi trans-sialidase peptide demonstrates high serological prevalence among infected populations across endemic regions.
Kortbawi HM, Marczak RJ, Rajan JV, et al. · J Clin Invest 2026
- Novel thrombolytic agents for acute ischemic stroke: A comprehensive review of current evidence.
Hotz JF, Kaindl L, Krebs S, et al. · J Neurol Sci 2025
- A 21-bp InDel in the promoter of STP1 selected during tomato improvement accounts for soluble solid content in fruits.
Wang Y, Shi C, Ge P, et al. · Hortic Res 2023
- Identification of Novel tRNA-Leu-CAA-Derived tsRNAs for the Diagnosis and Prognosis of Diffuse Gliomas.
Xu B, Liang J, Zou H, et al. · Cancer Manag Res 2022
Also in development for Ischemic Stroke
- OtaplimastatSP-8203Phase 31 trial
Shin Poong Pharmaceutical Co. Ltd. · Ischemic Stroke
- SecretomeConditioned, Umbilical Cord Mesenchymal Stem Cells derived ConditionedPhase 24 trials
PT. Prodia Stem Cell Indonesia · Acute Respiratory Distress Syndrome, Androgenetic Alopecia, Ischemic Stroke
- Umbilical Cord Mesenchymal Stem CellsMesenchymal stromal cells, Allogeneic Mesenchymal Stem CellsPhase 24 trials
PT. Prodia Stem Cell Indonesia · Diabetic Nephropathy Type 2, Ischemic Stroke, Cerebral Palsy
- NCS-01Phase 21 trial
NC Medial Research Inc · Ischemic Stroke
- TBO-309Phase 21 trial
ThromBio Pty. Ltd. · Ischemic Stroke, Tandem Occlusion
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.